Dattatreya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 26 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit -4.32%
(FY 2023)
- Ebitda -4.32%
(FY 2023)
- Net Worth -3.99%
(FY 2023)
- Total Assets 1.27%
(FY 2023)
About Dattatreya Pharmaceuticals
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shridhar Pittie and Sajjan Jhunjhunwala serve as directors at the Company.
- CIN/LLPIN
U24230GJ1998PTC034912
- Company No.
034912
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 1998
- Date of AGM
05 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dattatreya Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shridhar Pittie  | Director | 19-Apr-2007 | Current |
| Sajjan Jhunjhunwala | Director | 19-Apr-2007 | Current |
Financial Performance of Dattatreya Pharmaceuticals.
Dattatreya Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 4.32% decrease in profit. The company's net worth dipped by a decrease of 3.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dattatreya Pharmaceuticals?
In 2023, Dattatreya Pharmaceuticals had a promoter holding of 99.90% and a public holding of 0.10%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Samudra Enterprise Private LimitedActive 26 years 1 monthShridhar Pittie and Sajjan Jhunjhunwala are mutual person
- Ashwin Petrochemicals Private LimitedActive 27 years 25 days
Shridhar Pittie and Sajjan Jhunjhunwala are mutual person
- Rovik Shipping Private LimitedActive 26 years 11 months
Shridhar Pittie and Sajjan Jhunjhunwala are mutual person
- Mukundlal Bansilal And Sons Private LimitedActive 49 years 3 months
Shridhar Pittie is a mutual person
- Shree Nand Trading Company Private LimitedActive 49 years 4 months
Shridhar Pittie is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dattatreya Pharmaceuticals?
Unlock and access historical data on people associated with Dattatreya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dattatreya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dattatreya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
